PMID- 35600176
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220823
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Electronic)
IS  - 2049-0801 (Linking)
VI  - 78
DP  - 2022 Jun
TI  - Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors 
      in non-small cell lung cancer: A systematic review and meta-analysis.
PG  - 103752
LID - 10.1016/j.amsu.2022.103752 [doi]
LID - 103752
AB  - INTRODUCTION: Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment 
      modality for stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump 
      inhibitor (PPI) use can potentially reduce the clinical efficacy of ICIs; 
      however, the consensus in recent literature has been conflicting. This study aims 
      to analyze overall survival (OS) and progression-free survival (PFS) outcomes in 
      patients with NSCLC on ICI and concomitant PPI therapy. METHODS: A literature 
      search was done in 3 databases (Pubmed/Medline, Embase, and Cochrane Central). 
      All studies meeting the inclusion criteria assessing the impact of PPIs on the 
      efficacy of ICI in NSCLC patients were systematically identified. A 
      random-effects network meta-analysis evaluated OS and PFS in the two arms. 
      RESULTS: Four studies with 2,940 patients are included in our analysis. ICI usage 
      alone was associated with significantly better OS [HR = 1.46, 95% CI = 1.27-1.67, 
      P < 0.00001] and PFS [HR = 1.31, 95% CI = 1.17-1.47, P < 0.00001] when compared 
      to concomitant PPI and ICI therapy. CONCLUSION: The concomitant use of PPIs 
      during ICI therapy significantly worsens clinical outcomes with shorter OS and 
      increased risk of disease progression in patients with NSCLC.
CI  - (c) 2022 The Authors.
FAU - Dar, Sophia
AU  - Dar S
AD  - Hackensack University Medical Center, Hackensack, NJ, USA.
FAU - Merza, Nooraldin
AU  - Merza N
AD  - Department of Medicine, Wayne State University, Detroit, MI, USA.
FAU - Qatani, Ahmad
AU  - Qatani A
AD  - Hackensack University Medical Center, Hackensack, NJ, USA.
FAU - Rahim, Mehek
AU  - Rahim M
AD  - Hackensack University Medical Center, Hackensack, NJ, USA.
FAU - Varughese, Tony
AU  - Varughese T
AD  - Hackensack University Medical Center, Hackensack, NJ, USA.
FAU - Mohammad, Asna
AU  - Mohammad A
AD  - Hackensack University Medical Center, Hackensack, NJ, USA.
FAU - Masood, Fahad
AU  - Masood F
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Reza, Fizza Zehra
AU  - Reza FZ
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Wan, Schuchen
AU  - Wan S
AD  - Department of Medicine, Wayne State University, Detroit, MI, USA.
FAU - Almas, Talal
AU  - Almas T
AD  - Royal College of Surgeons in Ireland, Dublin, Ireland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220514
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC9119820
OTO - NOTNLM
OT  - Cancer
OT  - Immune checkpoint inhibitors
OT  - Non- small cell lung cancer
OT  - Proton pump inhibitor
OT  - Survival outcomes
EDAT- 2022/05/24 06:00
MHDA- 2022/05/24 06:01
PMCR- 2022/05/14
CRDT- 2022/05/23 03:49
PHST- 2022/03/12 00:00 [received]
PHST- 2022/05/06 00:00 [revised]
PHST- 2022/05/08 00:00 [accepted]
PHST- 2022/05/23 03:49 [entrez]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/24 06:01 [medline]
PHST- 2022/05/14 00:00 [pmc-release]
AID - S2049-0801(22)00512-X [pii]
AID - 103752 [pii]
AID - 10.1016/j.amsu.2022.103752 [doi]
PST - epublish
SO  - Ann Med Surg (Lond). 2022 May 14;78:103752. doi: 10.1016/j.amsu.2022.103752. 
      eCollection 2022 Jun.